Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06520982 · ClinicalTrials.gov registry record · Early Phase 1
Early Neurovascular Adaptations in Aging Women
A Early Phase 1 study of Aging and Women, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06520982: Recruiting Early Phase 1 study of Aging and Women, sponsored by University of Missouri-Columbia.
NCT06520982 is a Early Phase 1 study of Aging and Women that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 64 participants, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06520982, a Early Phase 1 study of Aging and Women, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
Our goal is to enhance our understanding of early vascular adaptations in aging women with an emphasis on the sympathetic nervous system.
Conditions Studied
Interventions
- DRUG Norepinephrine
- DRUG Isoproterenol
- DRUG Acetylcholine
- DRUG Nitroprusside
- DRUG Estrogen
Study Locations (1)
Missouri
- University of Missouri-Columbia - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2024-09-20 |
| Est. Completion | 2028-06-30 |
| Phase | Early Phase 1 |
What NCT06520982 shows while recruiting
NCT06520982 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 2,194-participant average among 262 other Aging trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Aging appearing as the primary indexed condition, and to 5 interventions - of which Norepinephrine is the first listed.
NCT06520982 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT06520982 about?
NCT06520982 is a clinical study titled "Early Neurovascular Adaptations in Aging Women". Our goal is to enhance our understanding of early vascular adaptations in aging women with an emphasis on the sympathetic nervous system.
What is the current status of trial NCT06520982?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 64 participants. The study started on 2024-09-20. Estimated completion is 2028-06-30.
What conditions does trial NCT06520982 study?
This clinical trial studies the following conditions: Aging, Women, Blood Flow, Sympathetic Nervous System.
What interventions are being tested in trial NCT06520982?
The interventions under investigation include: Norepinephrine (DRUG), Isoproterenol (DRUG), Acetylcholine (DRUG), Nitroprusside (DRUG), Estrogen (DRUG).
Who is sponsoring clinical trial NCT06520982?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06520982 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06520982's enrollment target sits among peer trials
64 133rd of 262 higher than 129 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gene Expression Changes In Young and Geriatric Skin
RECRUITING · Early Phase 1
-
Examining the Effects of Theta Burst TMS on Brain Connectivity and Balance Ability in Older Adults With Balance Problems
RECRUITING · Early Phase 1
-
Transient Receptor Potential Channels
RECRUITING · Early Phase 1
-
Heat, Microvascular Function and Aging
RECRUITING · Early Phase 1
-
Angiotensin-(1-7) Cardiovascular Effects in Aging
RECRUITING · Early Phase 1
-
Effects of Nicotine and Attention on Frequency Tuning in Auditory Cortex
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI